Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Anti-sense oligonucleotide of p21(waf1/cip1) prevents Interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells

Abstract

Elevation of the cyclin-dependent kinase (cdk) inhibitor, p27(kip1) is necessary for Interleukin (IL)-4-mediated growth arrest of human low grade astrocytoma (RTLGA) cells and occurs at 24 h of treatment. Pathways involved in IL-4 alteration of p27(kip1) are unknown, however. Here we investigated whether other cdk inhibitors contributed to the actions of IL-4 on RTLGA cells. By 12 h of IL-4 treatment, both cdk4 and cdk2 kinase activities against the retinoblastoma protein (pRb) were reduced and nuclear entry of pRb was prohibited. Twelve-hour cdk complexes contained elevated p21(waf1/cip1) but not p27(kip1), p15(ink4B) or p16(ink4A). IL-4 increased p21(waf1/cip1) but not p27(kip1) mRNA levels, and stimulated luciferase activity of a p21(waf1/cip1) promoter-luciferase reporter. In p53-mutant WITG3 cells, IL-4 did not alter p21(waf1/cip1) mRNA and promoter-luciferase activity or p27(kip1) protein, suggesting a need for functional p53. STAT6 phosphorylation by IL-4, however, occurred in both p53-mutant WITG3 and p53-functional RTLGA cells. Pre-treatment of RTLGA with anti-sense but not missense p21(waf1/cip1) oligonucleotide prior to IL-4: (a) restored cdk activities; (b) reduced cdk4-associated p21(waf1/cip1) levels; (c) prevented p27(kip1) elevation; and (d) reversed growth arrest. These results are the first to suggest that p21(waf1/cip1) is essential for IL-4-mediated elevation of p27(kip1) and growth arrest of astrocytoma cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

Abbreviations

AS:

antisense

BrdU:

bromodeoxyuridine

cdk:

cyclin-dependent kinase

EGF:

epidermal growth factor

FBS:

fetal bovine serum

IL-4:

interleukin 4

IP:

immunoprecipitation

MS:

missense

PBS:

phosphate-buffered saline

pRb:

retinoblastoma protein

RT–PCR:

reverse-transcribed polymerase chain reaction

SDS:

sodium dodecyl sulfate

STAT:

signal transducers and activators of transcription

TGF-β:

transforming growth factor beta

References

  • Agarwal ML, Taylor WR, Chernov MV, Chernova OB and Stark GR. . 1998 J. Biol. Chem. 273: 1–4.

  • Agrawal D, Hauser P, McPherson F, Dong F, Garcia A and Pledger WJ. . 1996 Mol. Cell. Biol. 16: 4327–4336.

  • Barna BP, Estes ML, Pettay J, Iwasaki K, Zhou P and Barnett GH. . 1995 J. Neuroimmunol. 60: 75–81.

  • Benedetti S, Bruzzone MG, Pollo B, DiMeco F, Magrassi L, Pirola B, Cirenei N, Columbo MP and Finocchiaro G. . 1999 Cancer Res. 59: 645–652.

  • Blanchard DA, Affredou MT and Vazquez A. . 1997 J. Immunol. 158: 3054–3061.

  • Brodie C and Goldreich N. . 1994 J. Neuroimmunol. 55: 91–97.

  • Brodie C, Goldreich N, Haiman T and Kazimirsky G. . 1998 J. Neuroimmunol. 81: 20–30.

  • Casaccia-Bonnefil P, Tikoo R, Kiyokawa H, Friedrich Jr V, Chao MV and Koff A. . 1997 Genes Dev. 11: 2335–2346.

  • Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM and Sherr CJ. . 1999 EMBO J. 18: 1571–1583.

  • Chin Y, Kotagawa M, Su W-C, You Z-H, Iwamoto Y and Fu X-Y. . 1996 Science 272: 719–722.

  • Coats S, Flanagan WM, Nourse J and Roberts JM. . 1996 Science 272: 877–880.

  • Damell Jr JE. . 1997 Science 277: 1630–1635.

  • Draetta G and Pagano M. . 1996 In: Topics in Biology, Wong WW . (ed.). Academic Press: NY. pp. 241–248.

    Google Scholar 

  • Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ and Reed SI. . 1994 Cell 76: 1013–1023.

  • El Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B. . 1993 Cell 75: 817–825.

  • El-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, Kinzler KW and Vogelstein B. . 1995 Cancer Res. 55: 2910–2929.

  • Estes ML, Iwasaki K, Jacobs BS and Barna BP. . 1993 Am. J. Pathol. 143: 337–341.

  • Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai L-H, Broudy V, Perlmutter RM, Kaushansky K and Roberts JM. . 1996 Cell 85: 733–744.

  • Hallevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GH, Beach D and Lassar AB. . 1995 Science 267: 1018–1021.

  • Hannon GJ and Beach D. . 1994 Nature 371: 257–261.

  • Harper JW. . 1997 Cancer Surv. 29: 91–107.

  • Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ. . 1993 Cell 75: 805–816.

  • Hengst L and Reed SI. . 1996 Science 271: 1861–1864.

  • Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K, Hamaoka T and Paul WE. . 1982 J. Exp. Med. 155: 914–923.

  • Johnson MR, Valentine C, Basilico C and Mansukhani A. . 1998 Oncogene 16: 2647–2656.

  • Kaplan MH, Daniel C, Schindler U and Grusby MJ. . 1998 Mol. Cell. Biol. 18: 1996–2003.

  • Kaplan MH, Schindler U, Smiley ST and Grusby MJ. . 1996 Immunity 4: 313–319.

  • Kato J, Matsuoka M, Polyak K, Massague J and Sherr CJ. . 1994 Cell 79: 487–496.

  • Kem SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW and Vogelstein B. . 1992 Science 256: 827–830.

  • Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA and Koff A. . 1996 Cell 85: 721–732.

  • Koff A and Polyak K. . 1995 Prog. Cell Cycle Res. 1: 141–147.

  • Kondo S, Barna BP, Kondo Y, Tanaka Y, Casey G, Liu J, Morimura T, Kaakaji R, Peterson JW, Werbel B and Barnett GH. . 1996 Oncogene 13: 1279–1285.

  • Kotanides H and Reich NC. . 1996 J. Biol. Chem. 271: 25555–25561.

  • Kwon TK, Buchholz MA, Ponsalle P, Chrest FJ and Nordin AA. . 1997 J. Immunol. 158: 5642–5648.

  • Levine AJ. . 1997 Cell 88: 323–331.

  • Liu J, Flanagan WM, Drazba JA, Estes ML, Barnett GH, Haqqi T, Kondo S and Barna BP. . 1997 J. Immunol. 159: 812–819.

  • Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM and Pagano M. . 1997 Nature Med. 3: 231–234.

  • Lois AF, Cooper LT, Geng YU, Nobori T and Carson D. . 1995 Cancer Res. 55: 4010–4013.

  • Lu B, Reichel M, Fisher DA, Smith JF and Rothman P. . 1997 J. Immunol. 159: 1255–1264.

  • MacLeod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B and Jacks T. . 1995 Genes Dev. 9: 935–944.

  • Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE and Givol D. . 1994 Cancer Res. 54: 3391–3395.

  • Millard SS, Yan JS, Nguyen H, Pagano M, Kiyokawa H and Koff A. . 1997 J. Biol. Chem. 272: 7093–7098.

  • Mitchell LC, Davis LS and Lipsky PE. . 1989 J. Immunol. 142: 1548–1552.

  • Morgan DO. . 1995 Nature 374: 131–134.

  • Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY and Nakayama K. . 1996 Cell 85: 707–720.

  • Noda A, Ning Y, Venable SF, Pereira SO and Smith JR. . 1994 Exp. Cell Res. 211: 90–98.

  • Noffz G, Qin Z, Kopf M and Blankenstein T. . 1998 J. Immunol. 160: 345–350.

  • O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monka A, Sausville EA, Weinstein JN, Friend S, Fornace Jr AJ and Kohn KW. . 1997 Cancer Res. 57: 4285–4300.

  • Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF and Rolfe M. . 1995 Science 269: 682–685.

  • Paul WE. . 1997 Ciba Foundation Sympos. 204: 208–219.

  • Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM and Koff A. . 1994a Genes Dev. 8: 9–22.

  • Polyak K, Lee MH, Erdjument BH, Koff A, Roberts JM, Tempst P and Massague J. . 1994b Cell 78: 59–66.

  • Puri RK. . 1995 Cancer Treat. Res. 80: 143–185.

  • Reifenberger G, Liu L, Ichimura K, Schmidt EE and Collins VP. . 1993 Cancer Res. 53: 2736–2739.

  • Reynisdottir I, Polyak K, Iavarone A and Massague J. . 1995 Genes Dev. 9: 1831–1845.

  • Sampson JH, Ashley DM, Archer GE, Fuchs HE, Dranoff G, Hale LP and Bigner DD. . 1997 Neurosurg. 41: 1365–1373.

  • Seidel HM, Milocco LH, Lamb P, Damell JE, Stein RB and Rosen J. . 1995 Proc. Natl. Acad. Sci. USA 92: 3041–3045.

  • Sherr CJ. . 1996 Science 274: 1672–1677.

  • Sherr CJ and Roberts JM. . 1995 Genes Dev. 9: 1149–1163.

  • Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, Chu C, Quelle FW, Nosaka T, Vignali DAA, Doherty PC, Grosveld G, Paul WE and Ihle JN. . 1996 Nature 380: 630–633.

  • Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA and EI Houseini M. . 1994 Oncogene 9: 3389–3396.

  • Sun P, Dong P, Dai K, Hannon GJ and Beach D. . 1998 Science 282: 2270–2272.

  • Suzumura A, Sawada M, Itoh Y and Marunouchi T. . 1994 J. Neuroimmunol. 53: 209–218.

  • Takeda K, Kishimoto T and Akira S. . 1997 J. Mol. Med. 75: 317–326.

  • Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, Kashiwamura S-I, Nakanishi K, Yoshido N, Kishimoto T and Akira S. . 1996 Nature 380: 627–630.

  • Tikoo R, Casaccia-Bonnefil P, Chao MV and Koff A. . 1997 J. Biol. Chem. 272: 442–447.

  • Toms SA, Hercbergs A, Liu J, Kondo S, Haqqi T, Casey G, Iwasaki K, Barnett GH and Barna BP. . 1998 J. Neurosurg. 88: 884–889.

  • Toyoshima H and Hunter T. . 1994 Cell 78: 67–74.

  • Waldman T, Kinzler KW and Vogelstein B. . 1995 Cancer Res. 55: 5187–5190.

  • Wei MX, Li F, Ono Y, Gauldie J and Chiocca EA. . 1998 J. NeuroVirol. 4: 237–241.

  • Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D. . 1993 Nature 366: 701–704.

  • Zeng Y-X and El-Deiry WS. . 1996 Oncogene 12: 1557–1564.

Download references

Acknowledgements

This work was supported by National Institutes of Health grant RO1NS-33932.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, J., Estes, M., Drazba, J. et al. Anti-sense oligonucleotide of p21(waf1/cip1) prevents Interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells. Oncogene 19, 661–669 (2000). https://doi.org/10.1038/sj.onc.1203373

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203373

Keywords

This article is cited by

Search

Quick links